Literature DB >> 29123442

Functional Effects of Alagebrium (ALT-711)-Isolated Rat Carotid Artery.

Cigdem Toprak1, Basar Sirmagul1, Semra Yigitaslan1.   

Abstract

OBJECTIVE: In our study, the effects of glycosylated protein cross-link breaker, alagebrium was investigated on isolated rat carotid artery using myography. Alagebrium showed vasodilator effect on carotid artery rings; particularly, this effect was significantly increased in endothelium-intact rings.
MATERIALS AND METHODS: To clarify the vasodilator mechanism of alagebrium, different antagonists such as N(G)-Nitro-L-arginine methyl ester (L-NAME), glibenclamide, indomethacin, metoprolol, propranolol, tetraethylammonium, and calcium channel activator BAYK-8644 were used to reverse this effect.
RESULTS: Relaxation% responses to alagebrium were more significantly increased in intact endothelium than in denuded arteries. Blocking vasodilation related to channels (K-ATP, PGI2, BKca) and receptors (ß1, ß2) did not reverse the relaxation response to alagebrium. Vasodilator response to alagebrium was only slightly decreased after L-NAME incubation and significantly decreased after BAYK-8644 incubation.
CONCLUSION: Results of present study suggest that the mechanism of alagebrium-induced vasodilator effect may include the blockage of L-type calcium channels and partially of the nitric oxide synthase enzyme.

Entities:  

Keywords:  Alagebrium; calcium channel blockage; carotid artery; nitric oxide; vasodilatation

Year:  2017        PMID: 29123442      PMCID: PMC5665628          DOI: 10.5152/eurasianjmed.2017.17046

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  20 in total

Review 1.  Advanced glycation end-products: a review.

Authors:  R Singh; A Barden; T Mori; L Beilin
Journal:  Diabetologia       Date:  2001-02       Impact factor: 10.122

2.  Improved arterial compliance by a novel advanced glycation end-product crosslink breaker.

Authors:  D A Kass; E P Shapiro; M Kawaguchi; A R Capriotti; A Scuteri; R C deGroof; E G Lakatta
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

Review 3.  Advanced glycation end products, their receptors and diabetic angiopathy.

Authors:  J L Wautier; P J Guillausseau
Journal:  Diabetes Metab       Date:  2001-11       Impact factor: 6.041

4.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice.

Authors:  M T Goova; J Li; T Kislinger; W Qu; Y Lu; L G Bucciarelli; S Nowygrod; B M Wolf; X Caliste; S F Yan; D M Stern; A M Schmidt
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  Non-genomic vasorelaxant effects of 17β-estradiol and progesterone in rat aorta are mediated by L-type Ca2+ current inhibition.

Authors:  Elisa Cairrão; Ezequiel Alvarez; João Miguel Carvas; Antonio Jose Santos-Silva; Ignacio Verde
Journal:  Acta Pharmacol Sin       Date:  2012-04-02       Impact factor: 6.150

6.  Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway.

Authors:  Po-Chiao Chang; Tso-Hsiao Chen; Chun-Jen Chang; Chun-Cheng Hou; Paul Chan; Horng-Mo Lee
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

7.  Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats.

Authors:  Bing Zhang; Kunlun He; Wei Chen; Xianfa Cheng; Hao Cui; Wu Zhong; Song Li; Lili Wang
Journal:  Hypertens Res       Date:  2014-06-26       Impact factor: 3.872

Review 8.  Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.

Authors:  Jasper W L Hartog; Adriaan A Voors; Stephan J L Bakker; Andries J Smit; Dirk J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2007-12       Impact factor: 15.534

Review 9.  Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease.

Authors:  Susan Zieman; David Kass
Journal:  Congest Heart Fail       Date:  2004 May-Jun

10.  Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling.

Authors:  Allyson L Kranstuber; Carlos Del Rio; Brandon J Biesiadecki; Robert L Hamlin; Joseph Ottobre; Sandor Gyorke; Véronique A Lacombe
Journal:  Front Physiol       Date:  2012-07-19       Impact factor: 4.566

View more
  1 in total

1.  Gut Microbiome-Derived Metabolite Trimethylamine N-Oxide Induces Aortic Stiffening and Increases Systolic Blood Pressure With Aging in Mice and Humans.

Authors:  Vienna E Brunt; Abigail G Casso; Rachel A Gioscia-Ryan; Zachary J Sapinsley; Brian P Ziemba; Zachary S Clayton; Amy E Bazzoni; Nicholas S VanDongen; James J Richey; David A Hutton; Melanie C Zigler; Andrew P Neilson; Kevin P Davy; Douglas R Seals
Journal:  Hypertension       Date:  2021-05-10       Impact factor: 9.897

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.